863 A multifaceted genetically engineered whole-cell vaccine platform generates potent, broad, persistent, and effector-centric anti-tumor immunity across multiple cancer indications
Year: 2026
Type: conference-abstract
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W7225187191
